| scholarly article | Q13442814 |
| P50 | author | Lynda D Roman | Q87687223 |
| Bradley J. Monk | Q107013145 | ||
| P2093 | author name string | Michael W Sill | |
| Robert A Burger | |||
| Thomas E Buekers | |||
| Heidi J Gray | |||
| P2860 | cites work | Global cancer statistics, 2002 | Q27860562 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials | Q30442543 | ||
| Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study | Q33330626 | ||
| Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group | Q33332609 | ||
| Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study | Q33503689 | ||
| A phase II trial of isotretinoin and alpha interferon in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study | Q33504661 | ||
| Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies | Q34599824 | ||
| Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets | Q36262349 | ||
| Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer | Q36284675 | ||
| Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions | Q36873084 | ||
| Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. | Q46035504 | ||
| Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study | Q46505904 | ||
| Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy | Q47800601 | ||
| Optimal flexible designs in phase II clinical trials. | Q52231249 | ||
| Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study | Q71215852 | ||
| Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Card | Q72708479 | ||
| Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group | Q73005845 | ||
| Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group | Q73358292 | ||
| The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination | Q81372797 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gynecologic oncology | Q5625186 |
| cervical squamous cell carcinoma | Q18556057 | ||
| phase II clinical trial | Q42824440 | ||
| bevacizumab | Q413299 | ||
| P304 | page(s) | 1069-1074 | |
| P577 | publication date | 2009-01-12 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study | |
| P478 | volume | 27 |
| Q41233511 | A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer |
| Q98628601 | A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer |
| Q84949996 | A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study |
| Q38669565 | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study |
| Q43279004 | A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. |
| Q37294922 | A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study |
| Q47562932 | A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort |
| Q37625473 | Adenocarcinoma: a unique cervical cancer |
| Q38184593 | Advances in cervical cancer pharmacotherapies |
| Q84160532 | Advances in cervical cancer treatment |
| Q34655335 | Angiogenesis and antiangiogenic agents in cervical cancer. |
| Q37622551 | Anti-angiogenesis agents in metastatic or recurrent cervical cancer |
| Q38115596 | Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment |
| Q39287099 | Antiangiogenics and immunotherapies in cervical cancer: an update and future's view |
| Q55001045 | Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review. |
| Q38653061 | Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). |
| Q48149693 | Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients |
| Q38706483 | Bevacizumab for the treatment of cervical cancer. |
| Q33859790 | Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. |
| Q36937771 | Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future |
| Q41484460 | CT-guided 125I interstitial brachytherapy for pelvic recurrent cervical carcinoma after radiotherapy |
| Q36442519 | Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial |
| Q52582301 | Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. |
| Q37546027 | Cervical cancer therapy: current, future and anti-angiogensis targeted treatment |
| Q34073257 | Cervical carcinoma manifesting as progressive bilateral visual loss |
| Q38554663 | Changing paradigms in the systemic treatment of advanced cervical cancer |
| Q38079973 | Chemoradiation in the management of cervix cancer: current status and future directions |
| Q36897266 | Chemotherapy and molecular targeting therapy for recurrent cervical cancer |
| Q90385073 | Chemotherapy and molecular therapy in cervical cancer |
| Q38070958 | Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials |
| Q34649620 | Chemotherapy of vulvar cancer: a review |
| Q36884393 | Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer |
| Q89493421 | Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer |
| Q46322974 | Clinical implications for cediranib in advanced cervical cancer |
| Q47957183 | Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010. |
| Q33680243 | Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence |
| Q91592081 | Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study |
| Q35564030 | Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers |
| Q84676387 | Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study |
| Q27023510 | Contemporary use of bevacizumab in ovarian cancer |
| Q38373926 | Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology |
| Q98770909 | Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer |
| Q37540968 | Emerging biological treatments for uterine cervical carcinoma. |
| Q38005222 | Emerging drugs for cervical cancer. |
| Q33620142 | Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix. |
| Q33386149 | Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer |
| Q92562854 | Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma |
| Q38319730 | Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer |
| Q54342333 | Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation. |
| Q26799484 | Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer |
| Q58699202 | Human papillomavirus and genome instability: from productive infection to cancer |
| Q38924824 | Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV. |
| Q38633525 | Immunotherapy and targeted therapy for cervical cancer: an update |
| Q38608730 | Immunotherapy in Gynecologic Cancers: Are We There Yet? |
| Q46457082 | Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study |
| Q33566222 | Improved survival with bevacizumab in advanced cervical cancer |
| Q38370237 | Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers. |
| Q38341324 | Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer |
| Q39168925 | Investigational drugs for the treatment of cervical cancer. |
| Q33944113 | Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer |
| Q38178742 | Management of advanced or recurrent cervical cancer: chemotherapy and beyond |
| Q30436395 | Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study |
| Q26830493 | Metronomic therapy for gynecologic cancers |
| Q41242728 | Molecular characterization of breast cancer CTCs associated with brain metastasis |
| Q38002719 | Molecularly targeted therapies in cervical cancer. A systematic review |
| Q35659915 | Monoclonal antibodies in gynecological cancer: a critical point of view |
| Q33407093 | Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer |
| Q58735557 | Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis |
| Q38592163 | Neoadjuvant chemotherapy in cervical cancer: an update |
| Q38175506 | New biological treatments for gynecological tumors: focus on angiogenesis |
| Q34700859 | New molecular targets against cervical cancer |
| Q38160897 | New pharmacotherapy options for cervical cancer |
| Q37036792 | Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond |
| Q35531393 | PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation |
| Q36092845 | Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy |
| Q28086919 | Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations |
| Q37773995 | Pharmacotherapy of cervical cancer. |
| Q37703190 | Pharmacotherapy options for locally advanced and advanced cervical cancer |
| Q33441115 | Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers |
| Q97528633 | Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study |
| Q38396745 | Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). |
| Q35023418 | Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study |
| Q35695168 | Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study |
| Q30434661 | Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study |
| Q98231702 | Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer |
| Q26774168 | Profile of bevacizumab and its potential in the treatment of cervical cancer |
| Q30354788 | Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. |
| Q54701760 | Results of concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after previous chemoradiation. |
| Q33771212 | Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies |
| Q39733019 | SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer |
| Q38077440 | Safety and feasibility of targeted agent combinations in solid tumours |
| Q38495486 | Systemic treatment of vulvar cancer |
| Q52611125 | Targeted Agents in Cervical Cancer: Beyond Bevacizumab. |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q64284091 | Targeted therapy in cervical cancer |
| Q53322899 | Targeted therapy in gynecologic cancers: Ready for prime time? |
| Q34389368 | Targeting angiogenesis in advanced cervical cancer |
| Q26824766 | Targeting angiogenesis in gynecologic cancers |
| Q37563976 | Targeting angiogenesis: progress with anti-VEGF treatment with large molecules |
| Q37692801 | Taxanes: their impact on gynecologic malignancy |
| Q90427159 | The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study |
| Q38810865 | The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer |
| Q35418973 | Therapeutic advances in women's cancers |
| Q40326668 | Thiazolidinediones abrogate cervical cancer growth |
| Q36216582 | Treatment options in recurrent cervical cancer (Review). |
| Q28550733 | Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy |
| Q89319590 | Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years |
| Q38178824 | Updates in systemic treatment for metastatic cervical cancer. |
| Q34253038 | Visible light optical spectroscopy is sensitive to neovascularization in the dysplastic cervix |
| Q36441220 | c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target. |
Search more.